

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME  
FOR THE PERIOD ENDED 30 NOVEMBER 2021

	2021 Current Quarter Ended 30-Nov RM'000	2020 Comparative Quarter Ended 30-Nov RM'000	2021 Cumulative Year To Date 30-Nov RM'000	2020 Cumulative Year To Date 30-Nov RM'000
<b>Income</b>				
Revenue	3,012	3,631	10,049	6,906
Cost of sales	(2,708)	(1,226)	(8,582)	(1,478)
<b>Gross Profit</b>	<b>303</b>	<b>2,405</b>	<b>1,467</b>	<b>5,428</b>
Other income	17	2,771	209	2,775
<b>Total Income</b>	<b>3,029</b>	<b>6,402</b>	<b>10,258</b>	<b>9,681</b>
<b>Expenses</b>				
Selling and distribution	(1,388)	(1)	(1,406)	(3)
Administrative and general expenses	(729)	(1,495)	(1,236)	(2,262)
<b>Profit / (Loss) from Operations (EBITA)</b>	<b>(1,796)</b>	<b>3,680</b>	<b>(966)</b>	<b>5,938</b>
Amortisation of Intangible Assets	(913)	(932)	(1,826)	(1,864)
Depreciation	(106)	(112)	(211)	(224)
<b>Profit / (Loss) Before Interest, Taxes (EBIT), Impairment and ESOS Expenses</b>	<b>(2,815)</b>	<b>2,636</b>	<b>(3,003)</b>	<b>3,850</b>
ESOS Expenses	(361)	-	(361)	-
<b>Profit / (Loss) Before Interest and Taxes</b>	<b>(3,176)</b>	<b>2,636</b>	<b>(3,364)</b>	<b>3,850</b>
Finance Cost	(24)	(23)	(48)	(45)
<b>Profit / (Loss) before Tax</b>	<b>(3,200)</b>	<b>2,613</b>	<b>(3,412)</b>	<b>3,805</b>
Profit / (Loss) before tax is stated after charging/(crediting):-				
Interest income	(31)	-	(69)	-
Reversal of impairment loss on trade receivables	-	(768)	-	(768)
Depreciation and amortisation	1,019	1,044	2,037	2,088
ESOS expenses	361	-	361	-
Foreign exchange (gain) / loss	9	761	57	922
Income tax expense	-	-	-	-
<b>Profit / (Loss) for the period</b>	<b>(3,200)</b>	<b>2,613</b>	<b>(3,412)</b>	<b>3,805</b>
Foreign currency translation	353	565	524	565
<b>Total Comprehensive Profit / (Loss)</b>	<b>(2,847)</b>	<b>3,178</b>	<b>(2,888)</b>	<b>4,370</b>
Attributable to :-				
Owners of the Company	(3,200)	2,613	(3,412)	3,805
Non-Controlling Interests	-	-	-	-
	<b>(3,200)</b>	<b>2,613</b>	<b>(3,412)</b>	<b>3,805</b>
Total comprehensive profit / (loss) attributable to:-				
Owners of the Company	(2,847)	3,178	(2,888)	4,370
Non-Controlling Interests	-	-	-	-
	<b>(2,847)</b>	<b>3,178</b>	<b>(2,888)</b>	<b>4,370</b>
Earnings / (Loss) per share - Basic (sen)	(0.51)	0.52	(0.55)	0.75
- Diluted (sen)	(0.49)	0.51	(0.53)	0.74

Note:

The Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the audited financial statements for the period ended 31 May 2021 and the accompanying explanatory notes attached to the interim financial statements.

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 NOVEMBER 2021**

	<b>As At 30 Nov 2021 RM'000</b>	<b>As At 31 May 2021 RM'000</b>
<b><u>ASSETS</u></b>		
<b>Non-Current Assets</b>		
Property, Plant and Equipment	170	297
Right-of-use Assets	92	171
Intangible Assets	19,201	21,027
Total Non-Current Assets	<u>19,463</u>	<u>21,495</u>
<b>Current Assets</b>		
Trade Receivables	28,499	25,716
Other Receivables	108	71
Tax Recoverable	548	441
Deposits, Cash and Bank Balances	16,494	18,646
Total Current Assets	<u>45,649</u>	<u>44,874</u>
<b>Total Assets</b>	<b><u>65,112</u></b>	<b><u>66,369</u></b>
<b><u>EQUITY AND LIABILITIES</u></b>		
<b>Capital and Reserves</b>		
Share Capital	45,912	45,912
Reserves	11,201	13,728
Total Equity	<u>57,113</u>	<u>59,640</u>
<b>Non-Current Liabilities</b>		
Trade and Other Payables	48	98
Total Non-Current Liabilities	<u>48</u>	<u>98</u>
<b>Current Liabilities</b>		
Trade Payables	7,741	6,238
Other Payables	114	216
Leased Liabilities	96	177
Bank Overdraft	-	-
Total Current Liabilities	<u>7,951</u>	<u>6,631</u>
Total Liabilities	<u>7,999</u>	<u>6,729</u>
<b>Total Equity and Liabilities</b>	<b><u>65,112</u></b>	<b><u>66,369</u></b>
Net Assets Per Share Attributable to owners of the Company (Sen)	9	10

Note:

**The Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the year ended 31 May 2021 and the accompanying explanatory notes attached to the interim financial statements.**

**UCREST BERHAD**

(Company No.: 420056-K)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
FOR THE PERIOD ENDED 30 NOVEMBER 2021**

	Share Capital RM'000	Foreign Currency translation Reserve RM'000	ESOS Reserve RM'000	Accumulated Loss RM'000	Equity Attributable to the Owners of the Company RM'000	Total Equity RM'000
<b><u>Quarter ended 30 Nov 2021</u></b>						
Balance as at 1 Jun 2021 (Audited), As previously stated	45,912	(11)	6,610	7,129	59,640	59,640
Issuance of shares	-	-	-	-	-	-
Share options granted under ESOS	-	-	361	-	361	361
Profit/(loss) for the period	-	524	-	(3,412)	(2,888)	(2,888)
Comprehensive profit/(loss) for the period	-	524	361	(3,412)	(2,527)	(2,527)
Balance as at 30 Nov 2021 (Unaudited)	45,912	513	6,971	3,717	57,113	57,113

Note:

**The condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 May 2021 and the accompanying notes attached to the interim financial statements.**

**CONDENSED CONSOLIDATED CASH FLOW STATEMENT  
FOR THE PERIOD ENDED 30 NOVEMBER 2021**

	<b>6 Months to date ended 30/11/2021 RM'000</b>	<b>12 Months to date ended 31/05/2021 RM'000</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit / (Loss) before tax	(3,412)	11,688
Adjustments for:		
Amortisation of intangible assets	1,826	3,653
Depreciation of property, plant and equipment	132	289
Depreciation of right-of-use asset	79	158
Impairment loss on trade receivables	-	1,340
Reversal of impairment loss on receivables	(220)	(9,057)
ESOS expenses	361	6,585
Finance costs	48	99
Interest income	(69)	(51)
Rent concession	-	(16)
Unrealised gain on foreign exchange translation	154	(378)
Unrealised loss on foreign exchange translation	(98)	303
Operating profit before changes in working capital	<u>(1,199)</u>	<u>14,613</u>
Changes in working capital:-		
Inventories	-	-
Trade and other receivables	(2,675)	(3,191)
Trade and other payables	1,449	(15,464)
Cash used in operations	<u>(2,425)</u>	<u>(4,042)</u>
Interest received	69	51
Tax paid	<u>(107)</u>	<u>(354)</u>
Net cash generated from / (used in) operating activities	<u>(2,463)</u>	<u>(4,345)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant & equipment	<u>(5)</u>	<u>(7)</u>
Net cash used in investing activities	<u>(5)</u>	<u>(7)</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceed from issuance of share capital		
- private placement	-	20,762
- pursuant to exercise of ESOS	-	1,954
Repayment to director	-	(604)
Repayment of lease liability	(81)	(150)
Interest paid	(48)	(4)
Net cash generated from / (used in) financing activities	<u>(129)</u>	<u>21,958</u>
<b>NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>(2,597)</b>	<b>17,606</b>
<b>CASH AND CASH EQUIVALENTS AT 01 JUNE</b>	<b>18,646</b>	<b>1,538</b>
<b>EFFECTS OF EXCHANGE RATE CHANGES</b>	<b>445</b>	<b>(498)</b>
<b>CASH AND CASH EQUIVALENTS AS AT END OF THE FINANCIAL PERIOD</b>	<b><u>16,494</u></b>	<b><u>18,646</u></b>

**Cash and cash equivalents**

Cash and cash equivalents included in the statements of cash flows comprise the following statements of financial position amounts:

Deposits	5,048	11,048
Cash and bank balances	11,446	7,598
	<u>16,494</u>	<u>18,646</u>

Note:

**The condensed consolidated cash flow statement should be read in conjunction with the audited financial statements for the year ended 31 May 2021 and the accompanying notes attached to the interim financial statements.**

**UCREST BERHAD**

(Company No.: 420056-K)

**SELECTED EXPLANATORY NOTES****1. Accounting Policies and Methods Of Computation**

The current quarter financial report ended 30 Nov 2021 is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standards ("MFRS") 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market.

The report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 May 2021. The explanatory notes attached to the quarterly financial report provide an explanation on events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 May 2021.

The accounting policies and methods of computation adopted by the Group in the quarterly financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 May 2021.

**2. Auditors' Report on Preceding Annual Financial Statements**

The auditors' report on the audited financial statements for the year ended 31 May 2021 was not qualified.

**3. Segmental Reporting****Geographical information**

	<u>Individual Quarter Ended</u>		<u>Individual YTD</u>	
	<u>30-Nov-21</u>	<u>30-Nov-20</u>	<u>30-Nov-21</u>	<u>30-Nov-20</u>
	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>
Malaysia	2	134	128	134
International	3,010	3,497	9,921	6,772
Group revenue	<b>3,012</b>	<b>3,631</b>	<b>10,049</b>	<b>6,906</b>

**4. Unusual Items**

During the quarter under review, there were no unusual items affecting assets, liabilities, equity, net income, or cash flows of the Group.

**5. Changes In Estimates Of Amount Reported Previously Affecting Current Interim Period**

There are no changes in estimates of amount reported that will have a material effect in the current interim period.

**6. Seasonality or Cyclicity**

The operations of the Group are not subject to any seasonality or cyclicity factors.

**7. Dividends Paid Or Proposed**

Dividends were neither paid nor proposed during the current interim period.

**8. Valuation of Property, Plant and Equipment**

The Group has not carried out any valuation on its property, plant & equipment.

**9. Debts and Equity Securities**

There were no issuances, cancellations, repurchases, resale and repayments of debt and equity securities.

**10. Change In The Composition of The Group**

There has been no change in the composition of the group for the quarter review.

**SELECTED EXPLANATORY NOTES****11. Discontinued Operation**

There were no discontinued operations within the activities of the Group for the quarter under review.

**12. Capital Commitments**

There were no capital commitments for the purchase of any property, plant and equipment or any other expenses that were not accounted for in the financial statements of the quarter under review.

**13. Changes In Contingent Liabilities & Assets**

There are no material contingent liabilities as at the date of this report.

**14. Subsequent Events**

There were no material events subsequent to the end of the reporting quarter that have not been reflected in the quarter under review.

**Additional Information As Per ACE Market Listing Requirement****15. Review Of Performance**

During the current quarter under review, the Group recorded a net loss attributable to Owners of the Company of RM3.200 million.

**16. Material Change In the Profit / (Loss) Before Taxation Compared To The Results of :-**

	<u>Immediate Preceding Quarter</u>		<u>Individual Quarter Ended</u>		<u>Individual YTD</u>	
	<u>30-Nov-21</u>	<u>31-Aug-21</u>	<u>30-Nov-21</u>	<u>30-Nov-20</u>	<u>30-Nov-21</u>	<u>30-Nov-20</u>
	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>
P/(L)BITDA	(1,796)	830	(1,796)	3,680	(966)	5,938
Less : Amortisation of intangible assets	(913)	(913)	(913)	(932)	(1,826)	(1,864)
Less : Depreciation	(106)	(105)	(106)	(112)	(211)	(224)
Less : ESOS expenses	(361)	-	(361)	-	(361)	-
Less : Impairment los on trade receivables	-	-	-	-	-	-
Less : Finance cost	(24)	(24)	(24)	(23)	(48)	(45)
Profit / (Loss) before tax	<u>(3,200)</u>	<u>(212)</u>	<u>(3,200)</u>	<u>2,613</u>	<u>(3,412)</u>	<u>3,805</u>

The Group recorded loss before tax of RM 3.200 million in the current quarter, and loss before tax of RM 0.212 million in the immediate preceding quarter.

**17. Commentary Of Prospects**

The technology transfer of Sputnik V vaccine is progressing slower than planned as there was some delay in the importation of materials due to recent regulatory changes. As the new variant Omicron is several times more contagious than Delta, the number of new cases spikes to the highest level in many countries. Generally, the market views that the demand of vaccines will continue in the foreseeable future. iMedic is selected by the Ministry of Health of Singapore as one of the platforms for providing the online medical services in the Home Recovery Program (HRP) where COVID-19 positive patients are to be quarantined and treated at home for 10 days. iMedic is awarded as the platform to manage the COVID-19 positive pregnant patients and chronic patients. With the recent surge of COVID-19 cases reaching almost 6,000 a day in Singapore, the number of patients under HRP is expected to increase correspondingly.

**18. Profit Forecast**

There was no profit forecast issued by the Group.

**19. Taxation**

There were no tax provision during the current interim period under review.

**20. Unquoted Investments / Properties**

There were no purchase or sales of unquoted investments or properties during the current interim period under review.

## SELECTED EXPLANATORY NOTES

### 21. Purchase or Disposal of Quoted Securities

There were no purchase or disposal of quoted securities during the current interim period under review.

### 22. Status of Corporate Proposal

The Company had at the Extraordinary General Meeting held on 22 January 2018 obtained the shareholders' approval for a private placement exercise to issue up to 106,901,642 new ordinary shares in the Company representing not more than twenty percent (20%) of the issued share capital of the company ("Private Placement").

94,303,575 new Ordinary Shares were issued pursuant to the Private Placement and were subsequently listed and quoted on the Ace Market of Bursa Malaysia Securities Berhad.

The details of the utilisation of proceeds from the Private Placement were as follows:-

Description	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance to be utilized (RM'000)
Payment for cost of sales	11,328	11,328	0
Payment of salaries	1,285	1,285	0
Payment of office rentals	161	161	0

The Proposed Private Placement is deemed completed on 17 December 2020.

The Company had at the Annual General Meeting held on 17 November 2020 obtained the shareholders' approval for a private placement exercise to issue up to 126,857,800 new ordinary shares in the Company representing not more than twenty percent (20%) of the issued share capital of the company ("Private Placement"). Subsequently, the Company had at the Annual General Meeting held on 12 November 2021 obtained the shareholders' approval for a general mandate to issued up to ten percent (10%) of its total number of issued shares.

As at the date of this report, 42,700,000 new Ordinary Shares were issued pursuant to the Private Placement and were subsequently listed and quoted on the Ace Market of Bursa Malaysia Securities Berhad.

The details of the utilisation of proceeds from the Private Placement were as follows:-

Description	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance to be utilized (RM'000)
Working capital	20,748	7,898	12,850
Expenses for the proposed private placement	184	90	94

### 23. Group Borrowings and Debt Securities

There were no borrowings and debts securities for the financial quarter under review.

### 24. Off Balance Sheet Financial Instruments

There were no off balance sheet financial instruments as at the date of this report.

### 25. Material Litigation

There were no Material Litigation for the financial quarter under review.

**SELECTED EXPLANATORY NOTES****26. Realised and Unrealised Profits/Losses**

On 25 March 2010, Bursa Securities issued a directive to all listed issuers pursuant to Rules 2.07 and 2.23 of Bursa Securities ACE Market Listing Requirements. The directive requires all listed issuers to disclose the breakdown of the unappropriated profits or accumulated losses as at the end of the reporting period, into realised and unrealised profits and losses.

On 20 December 2010, Bursa Securities further issued guidance on the disclose and the format period.

The breakdown of accumulated profit / (losses) of the Group as at the reporting date, into realised and unrealised losses, pursuant to the directive, is as follows:

	<b>Group</b>	
	<b><u>Unaudited</u></b> <b>30/11/2021</b> <b>RM'000</b>	<b><u>Audited</u></b> <b>31/05/2021</b> <b>RM'000</b>
Total accumulated profit / (losses) of UCrest Berhad and it's subsidiaries:		
- Realised	3,660	7,432
- Unrealised - in respect of other items of income and expense	57	(303)
Total Group accumulated profit as per consolidated accounts	<u>3,717</u>	<u>7,129</u>

The determination of realised and unrealised losses is based on the Guidedance of Special Matter No.1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Malaysia Securities Berhad Listing Requirements, issued by the Malaysian Institute of Accountants on 20 December 2010.

The disclosure of realised and unrealised losses above is solely for complying with the disclosure requirements stipulated in the directive of Bursa Malaysia and should not be applied for any other purposes.

**27. Dividends Payable**

The Board of Directors does not recommend any interim dividends for the current quarter ended 30 Nov 2021.

**28. Earnings / (Loss) Per Share**

## (a) Basic

The basic earnings / (loss) per share for the quarter and cumulative year to date are computed as follow:

	<b><u>Individual quarter ended</u></b>		<b><u>Cumulative YTD</u></b>	
	<b><u>Unaudited</u></b> <b>30-Nov-21</b>	<b><u>Unaudited</u></b> <b>30-Nov-20</b>	<b><u>Unaudited</u></b> <b>30-Nov-21</b>	<b><u>Audited</u></b> <b>30-Nov-20</b>
Net profit / (loss) attributable to owners of the company (RM'000)	(3,200)	2,613	(3,412)	3,805
Weighted average number of ordinary shares in issue ('000)	621,877	507,123	621,877	507,123
Basic earnings / (loss) per share (sen)	<u>(0.51)</u>	<u>0.52</u>	<u>(0.55)</u>	<u>0.75</u>

## (b) Diluted

The diluted earning / (loss) per share for the quarter and cumulative year to date are computed as follow:

	<b><u>Individual quarter ended</u></b>		<b><u>Cumulative YTD</u></b>	
	<b><u>Unaudited</u></b> <b>30-Nov-21</b>	<b><u>Unaudited</u></b> <b>30-Nov-20</b>	<b><u>Unaudited</u></b> <b>30-Nov-21</b>	<b><u>Audited</u></b> <b>30-Nov-20</b>
Net profit / (loss) attributable to owners of the company (RM'000)	(3,200)	2,613	(3,412)	3,805
Dilutive shares on option outstanding ('000)	652,373	512,862	647,417	513,327
Diluted earnings / (loss) per share (sen)	<u>(0.49)</u>	<u>0.51</u>	<u>(0.53)</u>	<u>0.74</u>